<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3825">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611243</url>
  </required_header>
  <id_info>
    <org_study_id>2020.229</org_study_id>
    <nct_id>NCT04611243</nct_id>
  </id_info>
  <brief_title>Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19</brief_title>
  <official_title>Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health and Medical Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      (a) Objectives&#xD;
&#xD;
        1. To assess the full lung function, exercise capacity, quality of life in patients with&#xD;
           COVID-19 over 2 years.&#xD;
&#xD;
        2. To assess the longevity of the serology response to SARS-CoV2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (b) Study design Adult patients (about 80) who have been discharged following treatment for&#xD;
      COVID-19 will be followed up at the Prince of Wales Hospital at 4 weeks after discharge, 6,&#xD;
      12, 18 and 24 months similar to our previous studies for SARS patients in 2003. The&#xD;
      assessment at each timepoint includes: lung volume (total lung capacity [TLC], vital&#xD;
      capacity, residual volume, functional residual capacity), spirometry (FVC, FEV1), diffusing&#xD;
      capacity of the lung for carbon monoxide (DLCO), 6-min walk distance, chest radiographs, and&#xD;
      Medical Outcomes Study 36-Item Short-Form General Health Survey questionnaire. In addition,&#xD;
      blood will be taken for ELISA to detect IgG and IgM antibody to the receptor-binding domain&#xD;
      of the spike protein of SARS-CoV-2 and evaluate its sensitivity and specificity together with&#xD;
      90% plaque reduction neutralization tests.&#xD;
&#xD;
      T cell assays for SARS-CoV will be carried out on the blood samples collected at 6 and 24&#xD;
      months.&#xD;
&#xD;
      (c) Expected outcome(s) This study will inform if there is any impairment of lung function,&#xD;
      exercise capacity and quality of life among patients with confirmed COVID-19. In addition the&#xD;
      study will provide data on the titre and longevity of the serology response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">May 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>spirometry</measure>
    <time_frame>2 years</time_frame>
    <description>FEV1 and FVC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung volume</measure>
    <time_frame>2 years</time_frame>
    <description>Litres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>2 years</time_frame>
    <description>meters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life by SF36 questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>scores in all domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serology and T cell response</measure>
    <time_frame>2 years</time_frame>
    <description>titers</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Function</condition>
  <condition>Exercise Capacity</condition>
  <condition>Quality of Life</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Kaletra, beta interferon +- ribavirin</arm_group_label>
    <description>Patients received lopinavir/ ritonavir 400mg/100mg (Kaletra) BD po for 7-14 days, Interferon beta-1b 0.25mg (8 MIU) subcutaneous alt day (maximum 7 doses) up to 14 days of symptom onset +- ribavirin 400mg bd for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remdesivir</arm_group_label>
    <description>Patients received remdesivir 200mg on first day followed by 100 mg daily for 5 to 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive treatment</arm_group_label>
    <description>Patients only received antipyretic as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kaletra and beta interferon</intervention_name>
    <description>kaletra and beta interferon vs remdesivir vs supportive treatment</description>
    <arm_group_label>Kaletra, beta interferon +- ribavirin</arm_group_label>
    <other_name>Remdesivir</other_name>
    <other_name>Supportive treatment</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be taken for serology testing and T cell response after discharge, 6, 12, 18 and&#xD;
      24 months.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (about 80) who have been discharged following treatment for COVID-19 will be&#xD;
        followed up at the Prince of Wales Hospital at 4 weeks after discharge, 6, 12, 18 and 24&#xD;
        months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients who have been discharged from hospital following treatment for&#xD;
        COVID-19 -&#xD;
&#xD;
        Exclusion Criteria: Unwilling to be follow up&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Hui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanna Ng, MBChB</last_name>
    <phone>85235053128</phone>
    <email>drsssng@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Yiu, BSc</last_name>
    <phone>85235053532</phone>
    <email>ysyiu@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna So-Shan Ng</last_name>
      <phone>3505 2785</phone>
      <email>drsssng123@yahoo.com.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Prof David Shu Cheong Hui</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>data pending</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

